China Medicine Receivables

China Medicine posts a receivables of $17M as of September 2010. That compares with $17M in the prior-year period — up 2.5% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China Medicine's receivables was $17M. The latest reading is $17M — a 2.5% year-over-year increase (period ending September 2010). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of China Medicine's financial statement story. At $17M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CHME's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; China Medicine's other metric pages and overview cover the third.